Answers are grounded in this paper and cite their sources.
Cancer is one of the leading causes of death around the world [1]. There are a number of challenges that the limitation of new drugs to potentiate antitumor therapies [2]. Furthermore, despite a positive response to initial treatment, many patients eventually develop a local recurrence and spread of the primary tumor [3–5]. Additional prognostic biomarkers are urgently needed to improve decision making regarding adjuvant therapy for these patients.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: